Alterra Labs Raises $12.5 Million Seed Round to Bridge AI’s Clinical Judgment Gap

Alterra Labs, a New York-based startup developing simulation environments for medical AI, has closed a $12.5 million seed funding round. The investment was led by Oak HC/FT, a prominent venture firm in the healthcare and fintech space, with additional participation from Flare Capital Partners and Company Ventures. While the company did not disclose its valuation, the round marks a significant entry for a startup founded just last year. Alterra aims to solve a persistent bottleneck in the deployment of clinical AI: the gap between a model’s raw medical knowledge and its ability to exercise safe, reliable judgment in real-world software environments.

The deal signals a shifting priority within the venture-backed AI ecosystem, moving away from simple data aggregation toward complex system evaluation. Vig Chandramouli, the partner at Oak HC/FT who led the investment, noted that the capital previously earmarked for data acquisition is now flowing into tools that help models "successfully do work." This transition reflects a broader realization in the Valley that frontier models often struggle when tasked with navigating the intricate workflows of electronic health records, insurer portals, and billing systems. By building realistic simulations of these platforms, Alterra provides a sandbox where AI can practice clinical and administrative tasks before deployment.

Alterra’s core product addresses the "judgment gap" identified by researchers at Stanford, who found that even advanced AI agents often fail to complete half of their assigned clinical tasks. Akash Kapoor, Alterra’s founder and CEO, observed that while models can learn to operate medical software, they often struggle with the uncertainty inherent in patient care. "The models don’t know when not to do something for a patient, and how to deal with uncertainty," Kapoor told Fortune. To bridge this, Alterra uses clinicians and scientists to design tasks and judge model decisions, turning that expert feedback into scoring criteria for reinforcement learning.

The startup’s trajectory highlights the increasing value of "clinical backbones" in the leadership of healthcare AI companies. Kapoor, who left Columbia Medical School in his final year to lead Alterra, combined a background in machine learning with years of medical training. This dual expertise is becoming a prerequisite for investors like Oak HC/FT, who argue that building these environments requires a deep understanding of both model behavior and clinical reality. For Alterra, this expertise translates into environments covering diverse sectors, including medical imaging, clinical trials, and telehealth, where models are tested on their ability to follow patients over time.

From a market perspective, Alterra’s customer base suggests that frontier AI labs are becoming the primary drivers of demand for specialized evaluation services. While the company also works with hospitals and medical societies, Kapoor identified frontier labs as the fastest-growing segment. These labs are increasingly reliant on post-training services and specialized environments to refine their general-purpose models for high-stakes medical applications. By generating revenue through these training environments, Alterra is positioning itself as a critical infrastructure layer in the race to commercialize medical AI, emphasizing safety and reliability over mere scale.

The company’s origins as ChartR in 2025 underscore the rapid pace of development in the sector. Initially focused on studying how models behaved in clinical settings, the startup pivoted toward building training environments after realizing that models frequently failed to recognize when they lacked sufficient information to act safely. This focus on safety is deeply personal for Kapoor, who founded the company following a personal experience with a missed cancer diagnosis. As medical knowledge continues to evolve, the need for continuous testing and training will likely keep Alterra’s services relevant, even as the underlying frontier models gain more native capabilities.